Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Recommendation of “Buy” from Brokerages

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has received a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy rating and three have issued a strong buy rating on the company.

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Finally, Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 20th.

Bayer Aktiengesellschaft Stock Up 0.6%

Shares of BAYRY stock opened at $13.58 on Monday. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. Bayer Aktiengesellschaft has a 1 year low of $5.30 and a 1 year high of $13.98. The firm’s fifty day moving average price is $11.88 and its two-hundred day moving average price is $9.44. The firm has a market capitalization of $53.37 billion, a P/E ratio of -150.87, a PEG ratio of 4.88 and a beta of 0.67.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.